Drug Evaluation, Preclinical
"Drug Evaluation, Preclinical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.
| Descriptor ID |
D004353
|
| MeSH Number(s) |
E05.295.750 E05.337.550
|
| Concept/Terms |
Drug Evaluation, Preclinical- Drug Evaluation, Preclinical
- Drug Evaluations, Preclinical
- Drug Screening
- Drug Screenings
- Screening, Drug
- Screenings, Drug
- Evaluation Studies, Drug, Pre-Clinical
- Preclinical Drug Evaluations
- Evaluation, Preclinical Drug
- Evaluations, Preclinical Drug
- Preclinical Drug Evaluation
- Drug Evaluation Studies, Preclinical
- Evaluation Studies, Drug, Preclinical
|
Below are MeSH descriptors whose meaning is more general than "Drug Evaluation, Preclinical".
Below are MeSH descriptors whose meaning is more specific than "Drug Evaluation, Preclinical".
This graph shows the total number of publications written about "Drug Evaluation, Preclinical" by people in this website by year, and whether "Drug Evaluation, Preclinical" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 4 | 4 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 2 | 4 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 1 | 3 |
| 2012 | 0 | 3 | 3 |
| 2013 | 2 | 2 | 4 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 2 | 2 |
| 2016 | 2 | 3 | 5 |
| 2017 | 12 | 50 | 62 |
| 2018 | 14 | 53 | 67 |
| 2019 | 2 | 16 | 18 |
| 2020 | 13 | 42 | 55 |
| 2021 | 13 | 29 | 42 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Evaluation, Preclinical" by people in Profiles.
-
Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies. Emerg Microbes Infect. 2021 Dec; 10(1):1790-1806.
-
Nucleic acid vaccines and CpG oligodeoxynucleotides for allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2021 12 01; 21(6):569-575.
-
Pan-selectin inhibitors as potential therapeutics for COVID-19 treatment: in silico screening study. Glycobiology. 2021 09 09; 31(8):975-987.
-
Construction of a Noninfectious SARS-CoV-2 Replicon for Antiviral-Drug Testing and Gene Function Studies. J Virol. 2021 08 25; 95(18):e0068721.
-
COVID19-associated cardiomyocyte dysfunction, arrhythmias and the effect of Canakinumab. PLoS One. 2021; 16(8):e0255976.
-
Screening out anti-inflammatory or anti-viral targets in Xuanfei Baidu Tang through a new technique of reverse finding target. Bioorg Chem. 2021 11; 116:105274.
-
Discovery of juglone and its derivatives as potent SARS-CoV-2 main proteinase inhibitors. Eur J Med Chem. 2021 Dec 05; 225:113789.
-
Inhibiting SARS-CoV-2 infection in vitro by suppressing its receptor, angiotensin-converting enzyme 2, via aryl-hydrocarbon receptor signal. Sci Rep. 2021 08 17; 11(1):16629.
-
Pharmacophore-Based Virtual Screening, Quantum Mechanics Calculations, and Molecular Dynamics Simulation Approaches Identified Potential Natural Antiviral Drug Candidates against MERS-CoV S1-NTD. Molecules. 2021 Aug 17; 26(16).
-
Identification of natural compounds as SARS-CoV-2 entry inhibitors by molecular docking-based virtual screening with bio-layer interferometry. Pharmacol Res. 2021 10; 172:105820.